Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 18 September 2019, 20:40 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019

TOKYO, Sept 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). This marks Eisai's sixth selection.

The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. The DJSI is one of the important investment criteria for the investors around the world who emphasize on corporate initiatives for improving non-financial value focused on environmental, social, and governance (ESG).

This year, the DJSI Asia Pacific has selected top 148 companies (76 of which are from Japan) from among the approximate major600 companies in the region. Eisai received high scores in categories such as Innovation Management, Cost Burden Addressing, Environment Policy and Management Systems, Product Quality and Recall Management as well as Human Rights.

In addition to the DJSI Asia Pacific, Eisai has been selected for the FTSE4Good Index Series, which isanother global benchmark SRI index as well as for the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index and S&P/JPX Carbon Efficient Index, which are the four ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


Sept 18, 2019 20:40 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Jan 20, 2020 14:21 HKT/SGT
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019
Jan 6, 2020 08:57 HKT/SGT
Eisai's Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China
Dec 24, 2019 16:22 HKT/SGT
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
Dec 23, 2019 08:17 HKT/SGT
U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients
Dec 10, 2019 08:02 HKT/SGT
Commencement of Major Renovation of Tsukuba Research Laboratories as Eisai Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and the World
Dec 9, 2019 08:36 HKT/SGT
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
Dec 9, 2019 08:17 HKT/SGT
Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer
Dec 5, 2019 08:11 HKT/SGT
Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium
Dec 2, 2019 08:23 HKT/SGT
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference
Dec 2, 2019 08:08 HKT/SGT
Eisai: Additional Indication for Lenvima (Lenvatinib) for Differentiated Thyroid Cancer Accepted in China
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: